Management of disturbed calcium metabolism in uraemic patients: 3. Potential perspectives--calcimimetics.
Schömig
M
M
Department of Internal Medicine, University of Heidelberg, Germany.
Ritz
E
E
D000814:Aniline Compounds / Q000627:therapeutic use*; D000818:Animals; D002116:Calcitonin / Q000627:therapeutic use*; D002118:Calcium / Q000819:agonists / Q000097:blood*; D002135:Calcium-Binding Proteins / Q000097:blood / Q000187:drug effects; D006801:Humans; D006934:Hypercalcemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D006996:Hypocalcemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D010281:Parathyroid Hormone / Q000097:blood; D010627:Phenethylamines; D011437:Propylamines; D016896:Treatment Outcome; D014511:Uremia / Q000097:blood / Q000150:complications*; D014807:Vitamin D / Q000627:therapeutic use*
D000814:Aniline Compounds; D002135:Calcium-Binding Proteins; C107873:N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine; D010281:Parathyroid Hormone; D010627:Phenethylamines; D011437:Propylamines; D014807:Vitamin D; D002116:Calcitonin; D002118:Calcium